INVIVYD INC. - COMMON STOCK

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

12 Apr 2023 06:00:00 By Nasdaq GlobeNewswire

Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19

30 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

23 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

22 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

16 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

06 Mar 2023 06:00:00 By Nasdaq GlobeNewswire

Invivyd Announces Changes to Executive Team

03 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways for Monoclonal Antibodies at FDA-EMA Workshop

19 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

06 Dec 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19

17 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights

10 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference

09 Nov 2022 06:00:03 By Nasdaq GlobeNewswire

Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights

02 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors

24 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform

13 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022

12 Oct 2022 15:01:00 By Nasdaq GlobeNewswire

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

12 Sep 2022 06:15:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces Corporate Name Change to Invivyd

12 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

06 Sep 2022 15:01:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

15 Aug 2022 05:30:00 By Nasdaq GlobeNewswire